Advaxis Inc. (ADXS)

0.45
0.04 7.80
NASDAQ : Health Technology
Prev Close 0.49
Open 0.50
Day Low/High 0.45 / 0.50
52 Wk Low/High 0.18 / 2.25
Volume 780.43K
Avg Volume 1.27M
Exchange NASDAQ
Shares Outstanding 69.74M
Market Cap 32.12M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Advaxis Announces Enrollment Of The First Patient In Its Phase 1/2 Trial For ADXS-HOT In The Treatment Of Non-Small Cell Lung Cancer

Advaxis Announces Enrollment Of The First Patient In Its Phase 1/2 Trial For ADXS-HOT In The Treatment Of Non-Small Cell Lung Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has initiated its Phase 1/2 clinical trial to evaluate ADXS-503, part of the Company's...

Advaxis Presents An Overview Of Its Lm Platform And Neoantigen-Directed Programs At The Immuno-Oncology 360° Conference

Advaxis Presents An Overview Of Its Lm Platform And Neoantigen-Directed Programs At The Immuno-Oncology 360° Conference

Advaxis, Inc. (NASDAQ:ADXS), (the Company) a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of the progression of its Lm platform from discovery to...

Advaxis To Present An Overview Of Its Lm Platform And New Information On Its Neoantigen-Directed Therapy Programs At The Immuno-Oncology 360° Conference

Advaxis To Present An Overview Of Its Lm Platform And New Information On Its Neoantigen-Directed Therapy Programs At The Immuno-Oncology 360° Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that an overview of the Company's proprietary Lm platform and new information regarding...

Data Highlighting Potential Benefits Of Lm Platform Presented At 2019 Keystone Symposia Conference On Cancer Vaccines

Data Highlighting Potential Benefits Of Lm Platform Presented At 2019 Keystone Symposia Conference On Cancer Vaccines

Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell...

Advaxis' Phase 3 AIM2CERV Study Placed On Partial Clinical Hold By FDA Related To CMC Requests

Advaxis' Phase 3 AIM2CERV Study Placed On Partial Clinical Hold By FDA Related To CMC Requests

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.

Advaxis Reports Fiscal Year 2018 Financial Results And Provides A Business Update

Advaxis Reports Fiscal Year 2018 Financial Results And Provides A Business Update

Advaxis, Inc. (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2018 and...

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Tuesday, January 15, 2019.

Advaxis To Present At LD Micro Main Event

Advaxis To Present At LD Micro Main Event

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC).

Advaxis Provides Update On Clinical Pipeline

Advaxis Provides Update On Clinical Pipeline

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded,...

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

  Advaxis, Inc. (NASDAQ: ADXS) ("Advaxis" or the "Company") announced today the closing of its previously announced underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended...

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis, Inc. (NASDAQ:ADXS) ("Advaxis" or the "Company") announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company") announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a...

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis Licenses ADXS-HER2 To OS Therapies For Evaluation In The Treatment Of Osteosarcoma

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development...

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For Non-Small Cell Lung Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis Provides Update On MAA Filing And ADXS-HOT Program

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a clinical update, as follows: Plans to withdraw its Conditional Marketing Authorization...

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis Announces Dosing Of First Patient With ADXS-NEO, An Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an...

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis Announces Prioritization Of Product Portfolio And Reports Fiscal 2018 Second Quarter Financial Results

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and...

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis Appoints Molly Henderson As Chief Financial Officer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial...

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Presented At ASCO Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer...

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Recently Presented Preclinical Data Show Potential For ADXS-NEO As Anti-Cancer Immunotherapy Agent

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of...

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Kenneth A. Berlin, President, CEO And Director Of Advaxis, Inc. (Photo: Business Wire)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Data Highlighting Advaxis' ADXS-PSA Accepted As Poster Presentation At The American Society Of Clinical Oncology Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has...

TheStreet Quant Rating: D (Sell)